NCT07321613

Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients

Effect of Thalidomide, Carmofur and Compound Mylabris Capsules (TCC) Cocktail Combined With Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone on Survival in Patients With Unresectable Hepatocellular Carcinoma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 545 (actual)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with conventional Transarterial Chemoembolization (TACE) for the treatment of patients with unresectable Hepatocellular Carcinoma (HCC).

Conditions

• Hepatocellular Cancer (HCC)

Interventions

Type	Name	Description
DRUG	Thalidomide (50mg)	Thalidomide tablets (Changzhou Pharmaceutical Factory, 50 mg qn)
DRUG	carmofur	carmofur tablets (Qilu Pharmaceutical, 100 mg, tid)
DRUG	compound mylabris capsule	CMC (Guizhou Yibai Pharmaceutical Co., Ltd, 750 mg, bid)
PROCEDURE	TACE	received initial treatment with traditional TACE by well-trained and experienced physicians

Timeline

• Start date: 2023-05-01
• Primary completion: 2025-05-01
• Completion: 2025-06-01
• First posted: 2026-01-07
• Last updated: 2026-01-07

Locations

1 site across 1 country: China